JP5504259B2 - 第ｉｘａ因子阻害剤としての複素環式化合物 - Google Patents
第ｉｘａ因子阻害剤としての複素環式化合物 Download PDFInfo
- Publication number
- JP5504259B2 JP5504259B2 JP2011510610A JP2011510610A JP5504259B2 JP 5504259 B2 JP5504259 B2 JP 5504259B2 JP 2011510610 A JP2011510610 A JP 2011510610A JP 2011510610 A JP2011510610 A JP 2011510610A JP 5504259 B2 JP5504259 B2 JP 5504259B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- aryl
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Bc1cc(-c([n]nc2C3=NC4=CC=C(*)CC4N3)c2O)ccc1 Chemical compound Bc1cc(-c([n]nc2C3=NC4=CC=C(*)CC4N3)c2O)ccc1 0.000 description 22
- BOZNWXQZCYZCSH-UHFFFAOYSA-N CCOC(CC(Cc1ccccc1)=O)=O Chemical compound CCOC(CC(Cc1ccccc1)=O)=O BOZNWXQZCYZCSH-UHFFFAOYSA-N 0.000 description 2
- UREFQWKAWKPMHK-UHFFFAOYSA-N Bc1cc(-c([nH]nc2-c([nH]c3c4)nc3ccc4OC)c2O)ccc1 Chemical compound Bc1cc(-c([nH]nc2-c([nH]c3c4)nc3ccc4OC)c2O)ccc1 UREFQWKAWKPMHK-UHFFFAOYSA-N 0.000 description 1
- SHZUGAIDQSTBNV-DAXSKMNVSA-N CC/C=C\C(C)Nc1nc(cccc2)c2[nH]1 Chemical compound CC/C=C\C(C)Nc1nc(cccc2)c2[nH]1 SHZUGAIDQSTBNV-DAXSKMNVSA-N 0.000 description 1
- IQHGJRGITYTCTQ-UHFFFAOYSA-N CC1C(c2c(C(Nc3cc(C#N)ccc3N)=C)[n](C)nc2C2=CC=CCC2)=C1 Chemical compound CC1C(c2c(C(Nc3cc(C#N)ccc3N)=C)[n](C)nc2C2=CC=CCC2)=C1 IQHGJRGITYTCTQ-UHFFFAOYSA-N 0.000 description 1
- XHSQCGLIUHLCAD-UHFFFAOYSA-N C[n](c(-c([nH]c1c2)nc1ccc2C(N)=O)c1OC)nc1-c1cccc(C=C)c1 Chemical compound C[n](c(-c([nH]c1c2)nc1ccc2C(N)=O)c1OC)nc1-c1cccc(C=C)c1 XHSQCGLIUHLCAD-UHFFFAOYSA-N 0.000 description 1
- WZPGFBGFZJDUER-UHFFFAOYSA-N C[n](c(C(Nc1ccc(CN)cc1)=O)c1O)nc1-c1ccccc1 Chemical compound C[n](c(C(Nc1ccc(CN)cc1)=O)c1O)nc1-c1ccccc1 WZPGFBGFZJDUER-UHFFFAOYSA-N 0.000 description 1
- NKKLRMMAYONDOZ-UHFFFAOYSA-N C[n](c(C(O)=O)c1OC)nc1-c1ccccc1 Chemical compound C[n](c(C(O)=O)c1OC)nc1-c1ccccc1 NKKLRMMAYONDOZ-UHFFFAOYSA-N 0.000 description 1
- JJEFSCCZZCCHEF-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[nH]c(C(OC)=O)c1O Chemical compound Cc(cc1)ccc1-c1n[nH]c(C(OC)=O)c1O JJEFSCCZZCCHEF-UHFFFAOYSA-N 0.000 description 1
- DJMBYVYUJWTSLY-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[n](C)c(-c2nc3cc(CNC)ccc3[nH]2)c1O Chemical compound Cc(cc1)ccc1-c1n[n](C)c(-c2nc3cc(CNC)ccc3[nH]2)c1O DJMBYVYUJWTSLY-UHFFFAOYSA-N 0.000 description 1
- UZAODEKUFLYINX-UHFFFAOYSA-N Cc1ccc2nc(-c([n](C)nc3-c4ccccc4)c3O)[nH]c2c1 Chemical compound Cc1ccc2nc(-c([n](C)nc3-c4ccccc4)c3O)[nH]c2c1 UZAODEKUFLYINX-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N O=C(Cc1ccccc1)Cl Chemical compound O=C(Cc1ccccc1)Cl VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- FUIIOTCIPMDQJB-UHFFFAOYSA-N Oc(cc1)cc2c1nc(C1=C=CCNC(c3ccccc3)=C1O)[nH]2 Chemical compound Oc(cc1)cc2c1nc(C1=C=CCNC(c3ccccc3)=C1O)[nH]2 FUIIOTCIPMDQJB-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5431008P | 2008-05-19 | 2008-05-19 | |
| US61/054,310 | 2008-05-19 | ||
| PCT/US2009/044291 WO2009143039A2 (en) | 2008-05-19 | 2009-05-18 | Heterocyclic compounds as factor ixa inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520967A JP2011520967A (ja) | 2011-07-21 |
| JP2011520967A5 JP2011520967A5 (https=) | 2012-06-07 |
| JP5504259B2 true JP5504259B2 (ja) | 2014-05-28 |
Family
ID=41066042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510610A Expired - Fee Related JP5504259B2 (ja) | 2008-05-19 | 2009-05-18 | 第ｉｘａ因子阻害剤としての複素環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8148363B2 (https=) |
| EP (2) | EP2300435A2 (https=) |
| JP (1) | JP5504259B2 (https=) |
| CN (1) | CN102099340A (https=) |
| AR (1) | AR071823A1 (https=) |
| CA (1) | CA2724430A1 (https=) |
| CL (1) | CL2009001214A1 (https=) |
| MX (1) | MX2010012635A (https=) |
| PE (1) | PE20091972A1 (https=) |
| TW (1) | TW201008930A (https=) |
| WO (1) | WO2009143039A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CA2803695A1 (en) | 2010-06-28 | 2012-01-05 | Bayer Intellectual Property Gmbh | Heteroaryl-substituted pyridine compounds for use as pesticides |
| EP2588465B1 (en) | 2010-06-30 | 2017-01-25 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CN107266433A (zh) | 2010-11-09 | 2017-10-20 | 铁木医药有限公司 | sGC刺激剂 |
| US9029399B2 (en) | 2011-04-28 | 2015-05-12 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| CN106117194A (zh) | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 |
| CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
| WO2014120346A1 (en) * | 2012-12-19 | 2014-08-07 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| WO2014099695A1 (en) * | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| BR112017004612A2 (pt) * | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| WO2016044645A1 (en) * | 2014-09-17 | 2016-03-24 | Elmaleh David R | Anticoagulant derivatives for cardiovascular imaging |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| WO2016087615A1 (en) | 2014-12-04 | 2016-06-09 | Procomcure Biotech Gmbh | Novel imidazole-based heterocyclic compounds |
| LT3226858T (lt) | 2014-12-04 | 2021-06-10 | Procomcure Biotech Gmbh | Imidazolo pagrindo antimikrobiniai agentai |
| WO2016133793A1 (en) * | 2015-02-16 | 2016-08-25 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| JP2019510802A (ja) * | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) * | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| WO2018093716A1 (en) * | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
| US11040947B2 (en) | 2017-03-22 | 2021-06-22 | The Research Foundation For The State University Of New York | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors |
| HUE062236T2 (hu) * | 2018-04-17 | 2023-10-28 | Univ Michigan Regents | Vérlemezke funkció inhibitorok és eljárás azok alkalmazására |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| EP4229050A4 (en) * | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
| CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7304078B2 (en) | 2002-04-16 | 2007-12-04 | Schering Corporation | Thrombin receptor antagonists |
| ES2291323T3 (es) | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
| BR0213967A (pt) | 2001-10-18 | 2005-08-30 | Schering Corp | Análogos de himbacina como antagonistas do receptor de trombina |
| BR0213562A (pt) * | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| CN1980665A (zh) * | 2004-07-07 | 2007-06-13 | 默克公司 | 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法 |
| WO2006014618A2 (en) * | 2004-07-22 | 2006-02-09 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| EP1797072A4 (en) * | 2004-09-17 | 2009-09-09 | Exelixis Inc | PYRAZOLKINASE MODULATORS AND USE METHOD |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| WO2009140342A1 (en) * | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
-
2009
- 2009-05-18 CL CL2009001214A patent/CL2009001214A1/es unknown
- 2009-05-18 EP EP09751268A patent/EP2300435A2/en not_active Ceased
- 2009-05-18 MX MX2010012635A patent/MX2010012635A/es active IP Right Grant
- 2009-05-18 WO PCT/US2009/044291 patent/WO2009143039A2/en not_active Ceased
- 2009-05-18 CA CA2724430A patent/CA2724430A1/en not_active Abandoned
- 2009-05-18 TW TW098116429A patent/TW201008930A/zh unknown
- 2009-05-18 JP JP2011510610A patent/JP5504259B2/ja not_active Expired - Fee Related
- 2009-05-18 CN CN200980128238XA patent/CN102099340A/zh active Pending
- 2009-05-18 EP EP14173412.9A patent/EP2805939B1/en not_active Not-in-force
- 2009-05-18 PE PE2009000694A patent/PE20091972A1/es not_active Application Discontinuation
- 2009-05-18 US US12/993,607 patent/US8148363B2/en active Active
- 2009-05-18 AR ARP090101778A patent/AR071823A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2724430A1 (en) | 2009-11-26 |
| EP2805939B1 (en) | 2018-06-27 |
| MX2010012635A (es) | 2010-12-06 |
| JP2011520967A (ja) | 2011-07-21 |
| TW201008930A (en) | 2010-03-01 |
| PE20091972A1 (es) | 2010-01-15 |
| US8148363B2 (en) | 2012-04-03 |
| EP2805939A1 (en) | 2014-11-26 |
| WO2009143039A3 (en) | 2010-07-08 |
| AR071823A1 (es) | 2010-07-14 |
| US20110065682A1 (en) | 2011-03-17 |
| CL2009001214A1 (es) | 2010-12-31 |
| EP2300435A2 (en) | 2011-03-30 |
| WO2009143039A2 (en) | 2009-11-26 |
| CN102099340A (zh) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5504259B2 (ja) | 第ｉｘａ因子阻害剤としての複素環式化合物 | |
| US8609676B2 (en) | 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors | |
| JP7579789B2 (ja) | 免疫調節剤、組成物およびその使用方法 | |
| ES2329881T3 (es) | Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa. | |
| JP4795336B2 (ja) | 血栓症病態の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト | |
| US20040132732A1 (en) | Quinazolinones and derivatives thereof as factor Xa inhibitors | |
| US20040209863A1 (en) | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | |
| US20050119266A1 (en) | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | |
| CN109790169A (zh) | 具有作为usp30抑制剂活性的氰基吡咯烷衍生物 | |
| MX2007012712A (es) | Fenil-acetamidas adecuadas como inhibidores de cinasa de proteina. | |
| AU2013276519B2 (en) | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | |
| RS57659B1 (sr) | Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia | |
| EP3131896B1 (en) | Factor ixa inhibitors | |
| KR20110075010A (ko) | 키나제 억제제로서 유용한 이미다조피리다진카르보니트릴 | |
| CA2648250A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| CN112521369A (zh) | 用于抑制fasn的化合物及组合物 | |
| US12371432B2 (en) | Haloallylamine compounds and application thereof | |
| US20030144287A1 (en) | Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl ] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors | |
| CN115894376B (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| CN109721613B (zh) | 含季铵离子的大环酰胺化合物及其药物组合物和用途 | |
| KR20250038764A (ko) | Tead 억제제 및 사용 방법 | |
| IL325136A (en) | Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a | |
| HK40053245A (en) | Haloallylamine compounds and application thereof | |
| KR20070022867A (ko) | 세린 프로테아제 억제제로서 유용한 6원 헤테로사이클 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120410 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131106 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140127 |
|
| TRDD | Decision of grant or rejection written | ||
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140214 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5504259 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| LAPS | Cancellation because of no payment of annual fees |